Claims for Patent: 8,829,013

Summary for Patent: 8,829,013

Title:	Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile
Abstract:	The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	Rodgers; James D. (Landenberg, PA), Li; Hui-Yin (Hockessin, DE)
Assignee:	Incyte Corporation (Wilmington, DE)
Application Number:	14/256,311
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,829,013
Patent Claims:	1. A method of treating a myeloproliferative disorder in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound that is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile phosphoric acid salt. 2. The method of claim 1, wherein the myeloproliferative disorder is polycythemia vera (PV). 3. The method of claim 1, wherein the myeloproliferative disorder is essential thrombocythemia (ET). 4. The method of claim 1, wherein the myeloproliferative disorder is myeloid metaplasia with myelofibrosis (MMM). 5. The method of claim 1, wherein (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile phosphoric acid salt is a crystalline salt. 6. The method of claim 5, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosp- horic acid salt. 7. A method of treating a myeloproliferative disorder in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile phosphoric acid salt and a pharmaceutically acceptable carrier. 8. The method of claim 7, wherein the myeloproliferative disorder is polycythemia vera (PV). 9. The method of claim 7, wherein the myeloproliferative disorder is essential thrombocythemia (ET). 10. The method of claim 7, wherein the myeloproliferative disorder is myeloid metaplasia with myelofibrosis (MMM). 11. The method of claim 7, wherein the pharmaceutical composition is suitable for oral administration. 12. The method of claim 7, wherein the pharmaceutical composition is in tablet form. 13. The method of claim 7, wherein (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile phosphoric acid salt is a crystalline salt. 14. The method of claim 13, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosp- horic acid salt.